Dose the first subject in the Phase 2a trial of FMX114
Delivered after the deadline (19 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 4 Mar 2021
- Due
- 30 Sep 2021
- Delivered
- 19 Oct 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Phase 2a FSI Anticipate Q3 2021”
What we found
Evidence strength A What the grades mean
The company announced first patient enrollment in its FMX114 Phase 1b/2a trial on October 19, 2021, after the Q3 2021 deadline.
-
A VYNE Therapeutics Inc. 8-K filed 2021-10-19
“today announced that it has enrolled the first patient in its Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis” ✓ confirmed on the page
-
A VYNE Therapeutics Inc. 10-Q filed 2021-11-10
“On October 19, 2021, we announced that the first patient was enrolled in our Phase 1b/2a clinical trial evaluating FMX114” ✓ confirmed on the page
Checked 27 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Dose
- Deliverable
- First subject in FMX114 Phase 2a trial
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you VYNE Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-YARW-025206 · Corrections policy